Skip to main content
    S

    Spero Therapeutics Inc (SPRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.05 (-5.35%)

    Market Cap: $58.26M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Spero Therapeutics Inc (SPRO) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Spero Therapeutics (SPRO) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Spero Therapeutics reported EPS of -$0.16, below the -$0.14 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    66%(21/32)
    Avg Surprise
    +9.73%

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.21
    Range-$0.26 - -$0.15
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.14
    Range-$0.14 - -$0.14
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$0.14
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    SPRO has an expected report date of Mar 24, 2027.

    SPRO Earnings Call

    The latest SPRO earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 32 quarters below that had an estimate, SPRO beat 21 and missed 11. The widest gap in the table came in the quarter ended Mar 31, 2024, when EPS landed 300.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16-$0.14-$0.14 - -$0.14-14.29%MissN/A11 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$0.16-$0.19N/A+15.79%BeatN/AN/AN/AAug 12, 2026N/A
    Mar 31, 2026-$0.13N/AN/AN/AN/AN/AN/AN/AMay 13, 2026$258000
    Dec 31, 2025$0.53-$0.20-$0.20 - -$0.20N/AN/AN/A11 up, 0 downMar 26, 2026$41.30M
    Sep 30, 2025-$0.13-$0.25-$0.25 - -$0.25+48.00%BeatN/A11 up, 0 downNov 13, 2025$5.44M
    Jun 30, 2025-$0.03-$0.38N/A+92.11%BeatN/A11 up, 0 downAug 12, 2025$14.19M
    Mar 31, 2025-$0.25-$0.44N/A+43.18%BeatN/A10 up, 1 downMay 13, 2025$5.87M
    Dec 31, 2024-$0.37-$0.31-$0.35 - -$0.27-18.35%Miss-138.2%22 up, 1 downMar 27, 2025$15.04M
    Sep 30, 2024-$0.32-$0.36-$0.56 - $0.02+11.11%Beat-900.0%31 up, 0 downNov 14, 2024$13.47M
    Jun 30, 2024-$0.33-$0.38-$0.45 - -$0.25+13.16%BeatN/A30 up, 0 downAug 5, 2024$10.20M
    Mar 31, 2024-$0.24-$0.06-$0.12 - $0.00-300.00%MissN/A30 up, 0 downMay 15, 2024$9.27M
    Dec 31, 2023$0.96-$0.10-$0.29 - $0.05N/AN/A+74.5%30 up, 0 downMar 13, 2024$73.52M
    Sep 30, 2023$0.04-$0.03-$0.24 - $0.21+233.33%BeatN/A31 up, 0 downNov 13, 2023$25.47M
    Jun 30, 2023-$0.23-$0.37-$0.46 - -$0.28+37.84%BeatN/A31 up, 0 downAug 10, 2023$2.72M
    Mar 31, 2023-$0.25-$0.26-$0.43 - -$0.26+3.85%BeatN/A30 up, 0 downMay 11, 2023$2.07M
    Dec 31, 2022$0.55$0.04-$0.40 - $0.87N/AN/AN/A30 up, 0 downMar 30, 2023$47.44M
    Sep 30, 2022-$0.33-$0.24-$0.43 - -$0.23-37.50%MissN/A30 up, 0 downNov 14, 2022$2.01M
    Jun 30, 2022-$0.43-$0.93N/A+53.76%BeatN/AN/A0 up, 0 downAug 10, 2022$1.99M
    Mar 31, 2022-$1.01-$0.95-$1.00 - -$0.80-6.32%MissN/A31 up, 0 downMay 16, 2022$2.07M
    Dec 31, 2021-$0.90-$0.75-$0.81 - -$0.61-20.00%MissN/A40 up, 0 downMar 31, 2022$2.74M
    Sep 30, 2021-$0.70-$0.66-$0.70 - -$0.60-6.06%MissN/A3N/ANov 10, 2021$3.06M
    Jun 30, 2021-$0.63-$0.75-$0.81 - -$0.69+16.00%BeatN/A4N/AAug 5, 2021$5.15M
    Mar 31, 2021-$0.66-$0.63-$0.74 - -$0.54-4.76%MissN/A4N/AMay 6, 2021$7.30M
    Dec 31, 2020-$0.68-$0.74-$0.97 - -$0.63+8.11%BeatN/A5N/AMar 11, 2021$1.91M
    Sep 30, 2020-$0.86-$0.89-$1.02 - -$0.76+3.37%BeatN/A6N/ANov 5, 2020$4.00M
    Jun 30, 2020-$0.85-$1.13-$1.37 - -$0.95+24.78%BeatN/A6N/AAug 6, 2020$1.73M
    Mar 31, 2020-$1.19-$1.25-$1.47 - -$0.74+4.80%BeatN/A6N/AMay 8, 2020$1.70M
    Dec 31, 2019-$1.36-$1.08-$1.23 - -$0.92-25.93%MissN/A6N/AMar 16, 2020$3.85M
    Sep 30, 2019-$0.95-$0.85-$1.09 - -$0.70-11.76%MissN/A6N/ANov 4, 2019$4.64M
    Jun 30, 2019-$0.74-$0.86-$0.98 - $0.19+13.95%BeatN/A5N/AAug 8, 2019$2.16M
    Mar 31, 2019-$0.29-$0.77-$0.85 - -$0.70+62.34%BeatN/A4N/AMay 9, 2019$7.72M
    Dec 31, 2018-$0.60-$0.75-$0.96 - -$0.61+20.00%BeatN/A5N/AMar 14, 2019$1.69M
    Sep 30, 2018-$0.60-$0.63-$0.73 - -$0.52+4.76%BeatN/A5N/ANov 8, 2018$658000
    Jun 30, 2018-$0.69-$0.77-$1.09 - -$0.15+10.39%BeatN/A6N/AAug 9, 2018$463000
    Mar 31, 2018-$0.74-$1.20-$1.67 - -$0.77+38.33%BeatN/A5N/AApr 2, 2018$1.15M
    Sep 30, 2017-$36.02-$35.07N/A-2.71%MissN/AN/AN/ADec 14, 2017$597000
    Jun 30, 2017-$2.96N/AN/AN/AN/AN/AN/AN/AAug 30, 2017$249000
    Mar 31, 2017-$0.51N/AN/AN/AN/AN/AN/AN/AJun 29, 2017$140000
    Last 38 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.12, a profit after a loss of $1.26 per share the year before. It was -$42.12 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.12N/A
    Dec 31, 2024-$1.26-341.7%
    Dec 31, 2023$0.52N/A
    Dec 31, 2022-$1.22N/A
    Dec 31, 2021-$2.89N/A
    Dec 31, 2020-$3.58N/A
    Dec 31, 2019-$3.34N/A
    Dec 31, 2018-$42.12N/A

    Earnings Calls

    The 3 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,300 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,2735
    2025Q2Jun 30, 20251,8066
    2024Q2Jun 30, 20243,3268

    2026Q2 Earnings Call

    Opening remarks

    Shai Biran Head of Investor Relations Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Spero Therapeutics released financial results and provided a business update for the second quarter of 2026. A press release is available on the Investor page of the Spero Therapeutics website. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. These forward-looking statements are based on Spero's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties associated with our business and factors that could cause or contribute to such differences are described in Spero's filings with the Securities and Exchange Commission, including in the Risk Factors section of the earnings report on Form 10-Q for the quarter ended June 30, 2026, filed today. Leading the call today are Esther Rajavelu, our President and Chief Executive Officer; and Dr. Debra Zack, our Chief Medical Officer. There will be a Q&A session following the prepared remarks. I will now turn the call over to Esther to begin.

    Esther Rajavelu President and Chief Executive Officer Thank you, Shai. Good afternoon, everyone, and thank you for joining us on our second quarter earnings and business update call. I will begin with key highlights from the quarter, outline our strategy and priorities going forward and then review our financial results. In the last 90 days, we had four major milestones. The FDA approved Utebzi, the first and only oral carbapenem for the treatment of complicated urinary tract infections, including pyelonephritis, which we developed with our licensing partner, GSK. We in-licensed SP001 and repositioned the company's pipeline to focus on immune-mediated diseases. We closed $105 million in nondilutive, nonrecourse financing, and we hired a Chief Medical Officer. Let me start with the last one by welcoming Dr. Debra Zack to the Spero team as our CMO. Deb is a board-certified rheumatologist with a PhD in immunology and extensive drug development experience spanning research, clinical development and medical affairs. She brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases, most recently as CMO at Exagen and before that in clinical leadership roles at Amgen, Xencor and Novartis. She officially joined Spero as CMO on August 3 to lead our clinical development strategy as we advance SP001 into the clinic. Deb, welcome. We are so glad you're here and look forward to your comments on SP001 later during this call. Let me now turn to the quarter.

    Frequently Asked Questions About SPRO

    When is Spero Therapeutics's next earnings date?

    Spero Therapeutics's next earnings report is expected for Mar 24, 2027.

    Did SPRO beat earnings estimates last quarter?

    No. Spero Therapeutics reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 14.29%.

    What EPS do analysts expect from SPRO next quarter?

    The consensus EPS estimate for Spero Therapeutics for the quarter ending Dec 31, 2026 is -$0.21 from 4 analysts, with estimates from -$0.26 to -$0.15.

    How often does SPRO beat earnings estimates?

    Spero Therapeutics beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +23.84%.